Atsushi Kanno1,2, Ichiro Yasuda3, Atsushi Irisawa4, Kazuo Hara5, Reiko Ashida6,7, Takuji Iwashita8, Mamoru Takenaka9, Akio Katanuma10, Tetsuya Takikawa1, Kensuke Kubota11, Hironari Kato12, Yousuke Nakai13, Shomei Ryozawa14, Masayuki Kitano7, Hiroyuki Isayama15, Hideki Kamada16, Yoshinobu Okabe17, Keiji Hanada18, Koushiro Ohtsubo19, Shinpei Doi20, Hiroyuki Hisai21, Goro Shibukawa22, Hiroo Imazu23, Atsushi Masamune1. 1. Division of Gastroenterology, Tohoku University Graduate School of Medicine, Miyagi, Japan. 2. Department of Medicine, Division of Gastroenterology, Jichi Medical University, Tochigi, Japan. 3. Third Department of Internal Medicine, University of Toyama, Toyama, Japan. 4. Department of Gastroenterology, Dokkyo Medical University School of Medicine, Tochigi, Japan. 5. Department of Gastroenterology, Aichi Cancer Center Hospital, Aichi, Japan. 6. Departments of Cancer Survey and Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan. 7. Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan. 8. First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan. 9. Department of Gastroenterology and Hepatology, Faculty of Medicine, Kindai University, Osaka, Japan. 10. Center for Gastroenterology, Teine Keijinkai Hospital, Hokkaido, Japan. 11. Department of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Kanagawa, Japan. 12. Department of Gastroenterology and Hepatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan. 13. Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. 14. Department of Gastroenterology, Saitama Medical University International Medical Center, Saitama, Japan. 15. Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan. 16. Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan. 17. Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan. 18. Department of Gastroenterology, JA Onomichi General Hospital, Hiroshima, Japan. 19. Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Ishikawa, Japan. 20. Department of Gastroenterology, Teikyo University Mizonokuchi Hospital, Kanagawa, Japan. 21. Department of Gastroenterology, Japanese Red Cross Date Hospital, Hokkaido, Japan. 22. Department of Gastroenterology, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan. 23. Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Abstract
BACKGROUND AND AIMS: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is used for the histopathological diagnosis of any type of gastrointestinal disease. Few adverse events are experienced with this procedure; however, the actual rate of adverse events remains unclear. This study aimed to clarify the current status of cases that experienced adverse events related to the EUS-FNA procedure used for histopathologic diagnoses. METHODS: A retrospective analysis of cases with EUS-FNA-related adverse events in Japanese tertiary centers was conducted by assessing the following clinical data: basic case information, FNA technique, type of procedural adverse events, and prognosis. RESULTS: Of the 13,566 EUS-FNA cases overall, the total number of cases in which adverse events related to EUS-FNA occurred was 234. The incidence of EUS-FNA-related adverse events was ~1.7%. Bleeding and pancreatitis cases accounted for ~49.1% and 26.5% of all adverse events, respectively. Bleeding was the most common adverse event with only seven cases requiring blood transfusion. In cases with neuroendocrine tumors, pancreatitis was the most frequent adverse event. Needle tract seeding because of EUS-FNA was observed during the follow-up period in only ~0.1% of cases with pancreatic cancer. There was no mortality because of adverse events caused by EUS-FNA. CONCLUSIONS: This study revealed that the adverse events-related EUS-FNA for histopathologic diagnoses were not severe conditions, and had low incidence.
BACKGROUND AND AIMS: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is used for the histopathological diagnosis of any type of gastrointestinal disease. Few adverse events are experienced with this procedure; however, the actual rate of adverse events remains unclear. This study aimed to clarify the current status of cases that experienced adverse events related to the EUS-FNA procedure used for histopathologic diagnoses. METHODS: A retrospective analysis of cases with EUS-FNA-related adverse events in Japanese tertiary centers was conducted by assessing the following clinical data: basic case information, FNA technique, type of procedural adverse events, and prognosis. RESULTS: Of the 13,566 EUS-FNA cases overall, the total number of cases in which adverse events related to EUS-FNA occurred was 234. The incidence of EUS-FNA-related adverse events was ~1.7%. Bleeding and pancreatitis cases accounted for ~49.1% and 26.5% of all adverse events, respectively. Bleeding was the most common adverse event with only seven cases requiring blood transfusion. In cases with neuroendocrine tumors, pancreatitis was the most frequent adverse event. Needle tract seeding because of EUS-FNA was observed during the follow-up period in only ~0.1% of cases with pancreatic cancer. There was no mortality because of adverse events caused by EUS-FNA. CONCLUSIONS: This study revealed that the adverse events-related EUS-FNA for histopathologic diagnoses were not severe conditions, and had low incidence.
Authors: Yasunobu Yamashita; Toshio Shimokawa; Reiko Ashida; Bertrand Napoléon; Andrea Lisotti; Pietro Fusaroli; Rodica Gincul; Christoph F Dietrich; Shunsuke Omoto; Masayuki Kitano Journal: Endosc Int Open Date: 2022-02-25